TG Therapeutics, Inc.
Price Action
Technical Summary
EMERGING TRENDTG Therapeutics, Inc. is attempting to emerge into an uptrend but lacks full moving average alignment. Relative strength is moderate (RS Rating: 67), indicating performance broadly in line with the market. Earnings growth of 286% provides fundamental context to the price action. However, price is extended 29% above the 50-day line, increasing the risk of a mean reversion.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $35.55 | +18.06% | ABOVE |
| 50 SMA | $32.58 | +28.83% | ABOVE |
| 100 SMA | $31.29 | +34.15% | ABOVE |
| 150 SMA | $31.92 | +31.50% | ABOVE |
| 200 SMA | $31.86 | +31.72% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is TGTX in an uptrend right now?
TGTX has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.
Is TGTX overbought or oversold?
TGTX's RSI (14) is 59. The stock is in neutral territory, neither overbought nor oversold.
Is TGTX outperforming the market?
TGTX has a Relative Strength (RS) Rating of 67 out of 99. TGTX is performing about average compared to the market.
Where is TGTX in its 52-week range?
TGTX is trading at $41.97, which is 100% of its 52-week high ($42.03) and 100% above its 52-week low ($25.28).
How volatile is TGTX?
TGTX has a Beta of 0.77 and 52-week volatility of 45%. It's less volatile than the S&P 500 - generally more stable.